ãã€ãªãã¯ãããžãŒäŒæ¥ã§ãã Inovio Pharmaceuticals, Inc. ã¯ãããããããŒããŠã€ã«ã¹ (HPV)ããããææçã«é¢é£ããçŸæ£ãæ²»çãã人ã
ãä¿è·ããããã® DNA å»è¬åã®çºèŠãéçºãåååã«éç¹ã眮ããŠããŸããå瀟㮠DNA å»è¬åãã©ãããã©ãŒã ã¯ããã现èãææçŽ°èã«å¯Ÿããå
ç«ç³»ã®èæ§ãæç ŽããäžèŽããªãç
åäœã®å€ç°äœãäžèŽããç
åäœã®å€ç°äœã«å¯Ÿãã系統éé²åŸ¡ãä¿é²ããæ©èœãæã€ã粟å¯ã«èšèšããã SynCon æé©åãã©ã¹ããã䜿çšããŠããŸããå瀟ã¯ãåå®®é žéšãå€é°éšãèéç°åœ¢æãªã©ã® HPV é¢é£åããç
å€ãé é žéšãåå®®é žéšãèéãé°èãå€é°éšãè£ãªã©ã® HPV é¢é£ãããåçºæ§åŒåžåšä¹³é è
«çãå€åœ¢ç¥çµè èœè
«ãåç«è
ºãããHIVããšãã©åºè¡ç±ãäžæ±åŒåžåšçå矀 (MERS)ãã©ããµç±ããžã«ãŠã€ã«ã¹ãªã©ã® DNA å»è¬åã®èšåºè©Šéšã®å®æœãšèšç»ã«æºãã£ãŠããŸããããã³COVID-19ãŠã€ã«ã¹ïŒã³ãããŠã€ã«ã¹ïŒã«å¯Ÿããã¯ã¯ãã³éçºã«åãçµãã§ããŸããããŒãããŒããã³ååè
ã«ã¯ãã¢ãããã€ãªç€Ÿãã¢ã¹ãã©ãŒãã«ç€Ÿãå京ã¢ãã¯ã¯ãã³çç©æè¡æéå
¬åžããã«ïŒã¡ãªã³ãã»ã²ã€ã財å£ãææçæµè¡å¯Ÿçã€ãããŒã·ã§ã³é£åïŒCEPIïŒãåœé²é«çç ç©¶èšç»å±ïŒDARPAïŒãHIVã¯ã¯ãã³è©Šéšãããã¯ãŒã¯ãåœéã¯ã¯ãã³ç ç©¶æãã«ãã«ãŠãŒããžã§ã³ããã¯ãå»çCBRNé²è¡ã³ã³ãœãŒã·ã¢ã ïŒMCDCïŒãåœç«ããç ç©¶æãåœç«è¡çç ç©¶æãåœç«ã¢ã¬ã«ã®ãŒææçç ç©¶æããªããžãŒãã€ãªãµãŒãã¹ç€ŸãããŒã«ãŒããå
ç«çæ³ç ç©¶æããã©ã³ãã©ã€ã³ã©ã€ããµã€ãšã³ã·ãºç€Ÿããªãžã§ããã³ç€ŸããµãŒã¢ãã£ãã·ã£ãŒãµã€ãšã³ãã£ãã£ãã¯ç€Ÿããã³ã·ã«ããã¢å€§åŠããŠã©ã«ã¿ãŒã»ãªãŒãéžè»ç ç©¶æããŠã£ã¹ã¿ãŒç ç©¶æãªã©ããããŸãããŸããå瀟ã¯Richter-Helm BioLogics GmbH & Co. KG瀟ãšãçŸåšCOVID-19ã®èšåºè©Šéšç¬¬Içžæ®µéã«ããæ²»éšçšDNAã¯ã¯ãã³INO-4800ã®ãµããŒãå¥çŽãçµãã§ããŸããåœéã¯ã¯ãã³ç ç©¶æããã³ãœãŠã«åœç«å€§åŠç
é¢ãšã®ææºãå瀟ã¯1979幎ã«èšç«ãããæ¬ç€Ÿã¯